Cellosaurus T24 (CVCL_0554)

Cell line name T24
Synonyms T-24; T 24
Accession CVCL_0554
Resource Identification Initiative To cite this cell line use: T24 (RRID:CVCL_0554)
Comments Part of: BLA-40 bladder carcinoma cell line panel.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MD Anderson Cell Lines Project.
Part of: UBC-40 urothelial bladder cancer cell line index.
Doubling time: 19 hours (PubMed=4133950); 21 hours (PubMed=3708594); ~48 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: GPI-anchored proteins analysis by proteomics.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_6876 (ACCS); CVCL_2029 (ECV-304); CVCL_2893 (EJ-1); CVCL_2443 (Ej138); CVCL_8199 (GHE); CVCL_8223 (hAG); CVCL_AT91 (HBMEC-2); CVCL_8229 (HCV-29TMV); CVCL_8238 (Hu456); CVCL_8239 (Hu549); CVCL_8242 (Hu609Tmv); CVCL_8243 (Hu961a); CVCL_4015 (JCA-1); CVCL_F660 (KS Y-1); CVCL_9826 (MGH-U2); CVCL_8271 (RAMAK-1); CVCL_3922 (SLT4); CVCL_2728 (T24/83); CVCL_Y181 (T24/DDP10); CVCL_Y182 (T24/DDP5); CVCL_Y183 (T24/DDP7); CVCL_M892 (T24T); CVCL_4014 (TSU-Pr1); CVCL_8155 (UM-UC-2); CVCL_M721 (UROtsa/F35)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): ATCC; CLS; Cosmic-CLP; DSMZ; JCRB; KCLB; PubMed=11416159; RCB; TKG

Markers:
AmelogeninX
CSF1PO10,12 (ATCC; CLS; Cosmic-CLP; DSMZ; JCRB; KCLB; PubMed=11416159; TKG)
12 (RCB)
D13S31712 (ATCC; CLS; Cosmic-CLP; JCRB; KCLB; RCB; TKG)
9,12 (DSMZ)
D16S5399
D18S5116,18
D21S1129
D3S135816,21 (CLS)
16 (KCLB)
D5S81810,12 (ATCC; CLS; Cosmic-CLP; DSMZ; JCRB; KCLB; PubMed=11416159; TKG)
10 (RCB)
D7S82010,11
D8S11799,14 (CLS)
14 (PubMed=11416159)
FGA17,22
Penta D11,15
Penta E7,10
TH016
TPOX8,11
vWA17 (ATCC; Cosmic-CLP; JCRB; RCB; TKG)
17,19 (CLS; DSMZ; KCLB; PubMed=11416159)
Web pages http://www.cells-talk.com/index.php/page/copelibrary?key=T24
http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/t/cell-lines-detail-335.html
http://tcpaportal.org/mclp/
Publications

PubMed=4133950; DOI=10.1002/ijc.2910110327
Bubenik J., Baresova M., Viklicky V., Jakoubkova J., Sainerova H., Donner J.
Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen.
Int. J. Cancer 11:765-773(1973)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=864752; DOI=10.1093/jnci/58.6.1743
Marshall C.J., Franks L.M., Carbonell A.W.
Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas.
J. Natl. Cancer Inst. 58:1743-1751(1977)

PubMed=870558; DOI=10.1177/25.4.870558
Benham F.J., Cottell D.C., Franks L.M., Wilson P.D.
Alkaline phosphatase activity in human bladder tumor cell lines.
J. Histochem. Cytochem. 25:266-274(1977)

PubMed=6244232
Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)

PubMed=7185004; DOI=10.2302/kjm.31.127
Tachibana M.
Studies on cellular adhesiveness in five different culture cell lines derived from carcinoma of the urinary bladder.
Keio J. Med. 31:127-148(1982)

PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=6823318; DOI=10.1038/301429a0
O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.
Identity of some human bladder cancer cell lines.
Nature 301:429-430(1983)

PubMed=6826254; DOI=10.1002/ijc.2910310308
Paulie S., Hansson Y., Lundblad M.L., Perlmann P.
Lectins as probes for identification of tumor-associated antigens on urothelial and colonic carcinoma cell lines.
Int. J. Cancer 31:297-303(1983)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3708594
Masters J.R.W., Hepburn P.J., Walker L., Highman W.J., Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.R., Franks L.M.
Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.
Cancer Res. 46:3630-3636(1986)

PubMed=2607719; DOI=10.5980/jpnjurol1989.80.988
Kihara K., Kageyama Y., Sumi S., Higashi Y., Fukui I., Oshima H.
A study of intercellular communication of human transitional cell carcinoma cell lines.
Nihon Hinyokika Gakkai Zasshi 80:988-994(1989)

PubMed=8873383; DOI=10.1007/BF00295899
Stadler W.M., Olopade O.I.
The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.
Urol. Res. 24:239-244(1996)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=9850064
Markl I.D.C., Jones P.A.
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
Cancer Res. 58:5348-5353(1998)

PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182
Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J., Carrato A., Tardon A., Serra C., Real F.X.
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Cancer Res. 66:7401-7404(2006)

PubMed=19375735; DOI=10.1016/j.juro.2009.01.108
Chiong E., Dadbin A., Harris L.D., Sabichi A.L., Grossman H.B.
The use of short tandem repeat profiling to characterize human bladder cancer cell lines.
J. Urol. 181:2737-2748(2009)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23401075; DOI=10.1002/path.4176
Guo Y., Chekaluk Y., Zhang J., Du J., Gray N.S., Wu C.-L., Kwiatkowski D.J.
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
J. Pathol. 230:17-27(2013)

PubMed=24367658; DOI=10.1371/journal.pone.0084411
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052
Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M., van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A., Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G., Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C., Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.
Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Eur. Urol. 65:360-366(2014)

PubMed=24459064; DOI=10.1007/s13277-013-1604-3
Pinto-Leite R., Carreira I., Melo J., Ferreira S.I., Ribeiro I., Ferreira J., Filipe M., Bernardo C., Arantes-Rodrigues R., Oliveira P., Santos L.
Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.
Tumor Biol. 35:4599-4617(2014)

PubMed=25997541; DOI=10.1186/s12864-015-1450-3
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S., Valencia A., Real F.X.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:403-403(2015)

PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
J. Proteomics 139:77-83(2016)

PubMed=27141528; DOI=10.1016/j.dib.2016.04.001
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Data Brief 7:1302-1305(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ATCC; HTB-4
BCRC; 60062
BCRJ; 0231
CLS; 300352/p619_T24
DSMZ; ACC-376
JCRB; JCRB0711
KCB; KCB 92027YJ
KCLB; 30004
RCB; RCB0431
RCB; RCB2536
TKG; TKG 0443
Cell line databases/resources CLDB; cl4452
CCLE; T24_URINARY_TRACT
CCRID; 3111C0001CCC000295
CCRID; 3131C0001000700055
CCRID; 3142C0001000000076
Cosmic-CLP; 724812
GDSC; 724812
LINCS_HMS; 50048
LINCS_LDP; LCL-1709
TOKU-E; 3252
Ontologies BTO; BTO:0001345
CLO; CLO_0009235
CLO; CLO_0009245
CLO; CLO_0050843
CLO; CLO_0050844
EFO; EFO_0002864
MCCL; MCC:0000455
Biological sample resources BioSample; SAMN03472744
BioSample; SAMN03473324
Chemistry resources ChEMBL-Cells; CHEMBL3307700
ChEMBL-Targets; CHEMBL614774
Gene expression databases GEO; GSM492493
GEO; GSM887683
GEO; GSM888775
GEO; GSM1374940
GEO; GSM1574571
GEO; GSM1670520
Polymorphism and mutation databases Cosmic; 716174
Cosmic; 724812
Cosmic; 755400
Cosmic; 845561
Cosmic; 846275
Cosmic; 925832
Cosmic; 928817
Cosmic; 943742
Cosmic; 1001664
Cosmic; 1016880
Cosmic; 1046673
Cosmic; 1285130
Cosmic; 1285985
Cosmic; 1302355
Cosmic; 1927302
Cosmic; 1938698
Cosmic; 2037960
Cosmic; 2050465
Cosmic; 2057459
Cosmic; 2444230
Proteomic databases PRIDE; PXD003105